CGTX
COGNITION THERAPEUTICS INCCompany Information
- Company Name
- COGNITION THERAPEUTICS INC
- CIK
- CIK0001455365
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- CGTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- CGTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-04-16
- Last sale
- —
- Shares purchased (TTM)
- 29,175
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 22,591,785
- Shares outstanding
- 90,624,381
- Ownership
- 24.93%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- -5.56%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 34 | 31 | 37 | 39 | 11 | 16 | 25 | 22 | 29 | 35 | 30 | 33 | ||||||
| Grants Receivable Current | 3 | 4 | 10 | 2 | 6 | 5 | 3 | 3 | 3 | 1 | 1 | 2 | ||||||
| Prepaid Expense Current | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | 2 | 3 | 1 | ||||||
| Restricted Cash Equivalents Current | 1 | 0 | 0 | 0 | 1 | - | - | - | - | - | - | - | ||||||
| Assets Current | 38 | 36 | 48 | 43 | 19 | 23 | 30 | 27 | 34 | 38 | 34 | 36 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets | - | - | - | - | - | - | - | - | - | - | - | 2 | ||||||
| Assets | 39 | 36 | 48 | 43 | 20 | 24 | 30 | 28 | 34 | 39 | 35 | 39 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 4 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 | 3 | ||||||
| Accrued Liabilities Current | 4 | 2 | 12 | 4 | 9 | 8 | 8 | 10 | 6 | 5 | 4 | 4 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Current | 0 | 0 | 0 | - | 0 | 0 | 0 | - | 0 | 0 | 1 | 0 | ||||||
| Liabilities Current | 5 | 6 | 14 | 7 | 12 | 11 | 11 | 13 | 11 | 10 | 10 | 8 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 0 | 1 | ||||||
| Liabilities | 6 | 6 | 14 | 7 | 13 | 11 | 11 | 13 | 11 | 10 | 11 | 10 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 240 | 233 | 233 | 232 | 197 | 196 | 194 | 182 | 180 | 179 | 166 | 162 | ||||||
| Retained Earnings Accumulated Deficit | -207 | -203 | -199 | -195 | -190 | -184 | -175 | -167 | -157 | -150 | -141 | -133 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | - | - | - | - | -0 | -0 | ||||||
| Stockholders Equity | 33 | 30 | 34 | 37 | 7 | 12 | 19 | 14 | 23 | 29 | 24 | 29 | ||||||
| Liabilities And Stockholders Equity | 39 | 36 | 48 | 43 | 20 | 24 | 30 | 28 | 34 | 39 | 35 | 39 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 95 | 89 | 89 | 88 | 65 | 62 | 60 | 41 | 40 | 40 | 32 | 30 | ||||||
| Shares Outstanding | 95 | 89 | 89 | 88 | 65 | 62 | 60 | 41 | 40 | 40 | 32 | 30 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCOGNITION THERAPEUTICS INC (CGTX) — SEC Financial Statements & Analysis
COGNITION THERAPEUTICS INC (CGTX) is a biological products, (no diagnostic substances) company, incorporated in DE. COGNITION THERAPEUTICS INC trades on Nasdaq as: CGTX. COGNITION THERAPEUTICS INC (CGTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, COGNITION THERAPEUTICS INC carries a market cap of $104.22M, a P/E ratio of -6.21x, a P/B ratio of 3.16x, an enterprise value of $69.46M, and an EV/EBITDA multiple of -1.90x. On profitability, it posts a Return on Equity (ROE) of -83.76% and a Return on Assets (ROA) of -57.33%. Per share, it reports EPS of $-0.19, diluted EPS of $-0.19, free cash flow per share of $-0.20, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -49.16% year-over-year and EPS growth of -64.27% year-over-year. On the balance sheet, it maintains a current ratio of 7.03x, a quick ratio of 6.92x, working capital of $32.85M, a debt-to-equity ratio of 0.18x, a debt ratio of 0.15, an interest coverage ratio of -1742.90x, free cash flow of $-17.70M (TTM), and net debt of $-34.76M. Figures sourced from SEC EDGAR.
- Market Cap
- $104.22M
- P/E TTM
- -6.21x
- EPS TTM
- $-0.19
- P/B TTM
- 3.16x
- ROE TTM
- -83.76%
- ROA TTM
- -57.33%
- Debt To Equity
- 0.18x
- Free Cash Flow TTM
- $-17.70M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is COGNITION THERAPEUTICS INC in?
COGNITION THERAPEUTICS INC (CGTX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does CGTX trade on?
COGNITION THERAPEUTICS INC (CGTX) trades on the Nasdaq.
Where is COGNITION THERAPEUTICS INC incorporated?
COGNITION THERAPEUTICS INC is incorporated in DE.
When was COGNITION THERAPEUTICS INC (CGTX)'s most recent SEC filing?
COGNITION THERAPEUTICS INC (CGTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is CGTX's market cap?
COGNITION THERAPEUTICS INC (CGTX) has a market capitalization of $104.22M as of 2026-06-30.
What is CGTX's EPS (earnings per share)?
COGNITION THERAPEUTICS INC (CGTX)'s trailing twelve month EPS is $-0.19 as of 2026-06-30.
What is CGTX's ROE (return on equity)?
COGNITION THERAPEUTICS INC (CGTX)'s trailing twelve month Return on Equity (ROE) is -83.76% as of 2026-06-30.
What is CGTX's ROA (return on assets)?
COGNITION THERAPEUTICS INC (CGTX)'s trailing twelve month Return on Assets (ROA) is -57.33% as of 2026-06-30.
What is CGTX's EV/EBITDA?
COGNITION THERAPEUTICS INC (CGTX)'s trailing twelve month EV/EBITDA is -1.90x as of 2026-06-30.